FAT1 Gene Expression in Iranian Acute Lymphoid and Myeloid Leukemia Patients

Mohammadreza Ostadali Dehagi; Shahrbano Rostami; Ahmadreza Shamshiri; Fatemeh Safari; Reza  Haji  Hosseini; Rick F. Thorne; Ardeshir Ghavamzadeh

doi:10.18502/ijhoscr.v17i2.12644

Mohammadreza Ostadali Dehagi Hematology, Oncology and Cell Therapy Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Shahrbano Rostami Hematology, Oncology and Cell Therapy Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Ahmadreza Shamshiri Research Center for Caries Prevention, Dentistry Research Institute, Department of Community Oral Health, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
Fatemeh Safari Department of Biology, Payame Noor University, Tehran, Iran
Reza Haji Hosseini Department of Biology, Payame Noor University, Tehran, Iran
Rick F. Thorne Translational Research Institute, Henan Provincial People’s Hospital, Academy of Medical Science, Zhengzhou University, Zhengzhou 450003, China
Ardeshir Ghavamzadeh Cancer & Cell Therapy Research Center, Tehran University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/ijhoscr.v17i2.12644

Keywords: FAT1; Cadherin; Acute Myeloid Leukemia (AML); Acute lymphoid leukemia (ALL); Leukemia

Abstract

Background: FAT atypical cadherin 1 (FAT1) is a member of the cadherin superfamily whose loss or gain is associated with the initiation and/or progression of different cancers. FAT1 overexpression has been reported in hematological malignancies. This research intended to investigate FAT1 gene expression in adult Iranian acute leukemia patients, compared to normal mobilized peripheral blood CD34+ cells.

Materials and Methods: The peripheral blast (peripheral blood mononuclear cells) cells of 22 acute myeloid leukemia (AML), 14 acute lymphoid leukemia (ALL) patients, and mobilized peripheral blood CD34+ cells of 12 healthy volunteer stem cell donors were collected. Then, quantitative real-time polymerase chain reaction (qPCR) was used to compare FAT1 gene expression.

Results: Overall, there were no significant differences in FAT1 expression between AML and ALL patients (p>0.2). Nonetheless, the mean expression level of FAT1 was significantly higher in leukemic patients (AML and ALL) than in normal CD34+ cells (p=0.029). Additionally, the FAT1 expression levels were significantly higher in both CD34+ and CD34- leukemic patients than in normal CD34+ cells (p=0.028).

Conclusion: No significant differences were found between FAT1 expression in CD34+ and CD34- leukemic samples (p> 0.3). Thus, higher FAT1 expression was evident in ALL and AML leukemia cells but this appeared unrelated to CD34 expression. This suggests in a proportion of adult acute leukemia, FAT1 expression may prove to be a suitable target for therapeutic strategies.